Intraoperative identification of the isocitrate dehydrogenase type 1 (IDH1) genotype, a key molecular marker in glioma, is essential for optimizing surgical strategies and tailoring post‐surgical treatments. This evidence concerns the gene IDH1 and central nervous system cancer.